Accessibility Menu
Clene logo

Clene(NASDAQ) CLNN

Current Price$5.75
Market Cap$74.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-97%
5 Year-97%
1 Year+51%
1 Month-3%
Clene last closing stock price
MetricPriceDate
Last closeUSD 5.852026-07-21
Clene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.49%USD 6.192026-07-14
1 month-2.66%USD 6.012026-06-18
3 month-10.96%USD 6.572026-04-22
Year to date-0.34%USD 5.872025-12-31
1 year+51.16%USD 3.872025-07-21
3 year-63.44%USD 16.002023-07-21
5 year-96.81%USD 183.602021-07-22
Since inception-96.97%USD 193.002018-08-27

Clene Financials at a Glance

Market Cap

$74.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$134.00K

Net Income (TTM)

-$33.51M

EPS (TTM)

-$3.21

P/E Ratio

-1.82

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$5.75

Volume

1,407

Open

$5.90

Previous Close

$5.75

Daily Range

$5.71 - $5.90

52-Week Range

$3.25 - $13.50

Estimated Earnings Date

Aug 13, 2026

CLNN News

Foolcom-Featured.png

Clene Posts 70% Revenue Drop in Q2

Motley Fool Markets TeamAug 14, 2025
abbvie

Why Shares of Clene Jumped 11.8% on Monday

James HalleyJul 18, 2022
GettyImages-652397564

Why Clene Stock Skyrocketed Today

Prosper Junior BakinyFeb 3, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clene

Clene develops new treatments for brain and nerve diseases like ALS and MS. Its main product, CNM-Au8, aims to help people with these conditions. The company also sells dietary supplements for general health support.

What’s on the Clene Menu?

  • CNM-Au8 (Lead Drug): Gold nanocrystal suspension for ALS, MS, and Parkinson’s disease; no pharmaceutical revenue yet.
  • CNM-AgZn17: Silver and zinc gel for infections and wound healing; not yet commercialized.
  • CNM-ZnAg: Antiviral and antibacterial agent, including for COVID-19; not yet commercialized.
  • CNM-PtAu7: Gold-platinum nanocrystal for cancer treatment; in early development.
  • Dietary Supplements: rMetx and KHC46, zinc-silver and gold supplements; 3.7% of total revenue in Q2 2025.

Growth and Expansion: The Clene Timeline

  • Launched CNM-Au8 clinical trials for ALS and MS (2019–2025).
  • Secured NIH grant in 2023 for ALS research and expanded access program.
  • Formed exclusive distribution partnership with 4Life for dietary supplements (2018).
  • Expanded supplement sales through subsidiary dOrbital.
  • Planned new clinical trial for Parkinson’s disease (2025).

What Makes Clene Stand Out?

Clene uses a unique process to make clean-surfaced nanocrystal drugs, avoiding common chemical residues. Its focus is on diseases with few treatment options, targeting how cells produce energy. The company relies on U.S. distribution and a single main customer for supplement sales.

Five Things You Need to Know

  • Revenue was $27,000 in Q2 2025, down 70.3% from Q2 2024.
  • All product revenue in Q2 2025 came from dietary supplements via 4Life.
  • Net loss was $7.4 million in Q2 2025, up from $6.8 million in Q2 2024.
  • Cash and cash equivalents were $7.3 million as of June 30, 2025.
  • Clene reported an accumulated deficit of $290.3 million as of June 2025.

Bottom Line

Clene is a small biotech focused on new therapies for nerve diseases and supplements. Its future depends on clinical trial progress and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

79

CEO

Robert Dee Etherington, MBA

Website

www.clene.com

Headquarters

Salt Lake City, UT 84121, US

CLNN Financials

Key Financial Metrics (TTM)

Gross Margin

-182.09%

Operating Margin

-15535.07%

Net Income Margin

-25009.70%

Return on Equity

233.93%

Return on Capital

-565.62%

Return on Assets

-154.69%

Earnings Yield

-54.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$74.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.78M

Volume

1.41K

Avg. Volume

494.87K

Financials (TTM)

Gross Profit

-$244.00K

Operating Income

-$20.82M

EBITDA

-$29.20M

Operating Cash Flow

-$18.08M

Capital Expenditure

-$39.03K

Free Cash Flow

-$18.12M

Cash & ST Invst.

$5.94M

Total Debt

$22.05M

Clene Performance Analysis

Clene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 473,000-34.6%
20232023-12-31USD 654,00038.3%
20242024-12-31USD 342,000-47.7%
20252025-12-31USD 200,000-41.5%
Clene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-66.7%
Q32025-09-30-44.4%
Q42025-12-31413.3%
Q12026-03-31-80.5%
Clene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -9.18190.0%
20232023-12-31USD -9.432.8%
20242024-12-31USD -5.67-39.9%
20252025-12-31USD -2.65-53.1%
Clene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-816.6%
Q32025-09-30-9.0%
Q42025-12-31-9.4%
Q12026-03-3125.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$15.00K

-81.5%

Gross Profit

-$340.00K

-657.4%

Gross Margin

-22.67%

N/A

Market Cap

$74.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$946.24K

N/A

Employees

79

N/A

Net Income

-$8.09M

-977.4%

EBITDA

-$6.94M

-2760.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.94M

-39.6%

Total Debt

$22.05M

+5.3%

Accounts Receivable

$3.51M

+132.4%

Inventory

$54.00K

+42.1%

Long Term Debt

$19.36M

+15.0%

Short Term Debt

$2.69M

-34.4%

Return on Assets

-1.55%

N/A

Return on Invested Capital

-1.39%

N/A

Free Cash Flow

-$4.53M

+9.6%

Operating Cash Flow

-$4.53M

+9.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COYACoya Therapeutics, Inc.
$4.37-3.96%
PLRXPliant Therapeutics, Inc.
$1.10+0.92%
CNTXContext Therapeutics Inc.
$0.61-2.63%
CNTBConnect Biopharma Holdings Limited
$2.20-0.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%

Questions About CLNN

What is the current price of Clene?

Clene is trading at $5.75 per share.

What is the 52-week range for Clene?

Over the past 52 weeks, Clene has traded between $3.25 and $13.50.

How much debt does Clene have?

As of the most recent reporting period, Clene reported total debt of $22.05M.

How much cash does Clene have on hand?

Clene reported $5.94M in cash and cash equivalents in its most recent financial results.

What is Clene’s dividend yield?

Clene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services